Purpose: Cannabidiol (CBD) is a non-psychotropic phytocannabinoid extracted from cannabis sativa. CBD and its derivatives have been used against neuropsychiatric disorders as a traditional medicine for centuries. Nowadays, CBD as an anti-convulsant is used to treat childhood onset epilepsy. However, the oral bioavailability of CBD is around 6% due to its limited aqueous solubility. The goal of the current project is to develop an aqueous liquid formulation that can significantly increase drug solubility and is suitable for oral administration of CBD in pediatric epileptic patients.
Methods: The CBD-loaded nanoformulation was prepared by a solvent evaporation method. CBD (2.5 mg), Poloxamer 407 (37.5 mg) were dissolved in chloroform (1 ml) in a 50 ml round-bottom flask. A homogeneous thin drug-polymer film was formed by rotary evaporation and dried overnight under vacuum to remove any residual solvent. The film was hydrated in 1.5 ml 10 mM HEPES saline buffer and centrifuged at highest speed for 5 min to remove any undissolved polymer. The loading concentration of CBD was quantified by GC-MS. The size of nanoformulation was analyzed by dynamic light scattering (DLS) using Nano Zetasizer.
Results: CBD can be efficiently loaded into Poloxamer 407-based nanoformulation. Minimal precipitation was observed. The loading efficiency of CBD is ≥ 95%. The average hydrodiameter of CBD-loaded nanocarrier has a size at 20 nm (Fig. 1) with narrow distribution. The average size remains unchanged after 3 days storage at room temperature.
Conclusion: Poloxamer 407-based nanoformulation is a promising delivery system for CBD. Further studies are warranted to evaluate this formulation in animal models.
Goutam Mondal– Postdoc, University of Mississippi
Mahmoud Elsohly– University of Mississippi
Nigel Langley– BASF Corporation, New York
Chalet Tan– Associate professor, University of Mississippi, Mississippi